Reduction of albuminuria by a calcium antagonist, manidipine, in rats with passive Heymann nephritis.
We evaluated the effects of a novel calcium antagonist, manidipine, on albuminuria in rats with passive Heymann nephritis (PHN). Treatment with 0.05% manidipine significantly reduced urinary albumin excretion (62.1 +/- 7.5 vs. 46.9 +/- 8.5 mg/urinary creatinine excretion mg, P < 0.05) and attenuated lipid peroxidation of the renal cortices (0.97 +/- 0.08 vs 0.84 +/- 0.11 nM MDA/mg protein, P < 0.05) on day 14 in PHN. Manidipine affected neither the light microscopic, immunofluorescent nor electron microscopic findings. These results indicate that manidipine reduced proteinuria in rats with PHN, and that its antiproteinuric effect was associated with the reduction of lipid peroxidation.
Arai
T
T
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Kobayashi
S
S
Nakajima
T
T
Hishida
A
A
D000419:Albuminuria / Q000188:drug therapy*; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004095:Dihydropyridines / Q000494:pharmacology / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000150:complications*; D007672:Kidney Cortex / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D009578:Nitrobenzenes; D010879:Piperazines; D051381:Rats
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009578:Nitrobenzenes; D010879:Piperazines; C054218:manidipine; D003404:Creatinine